Schizophrenia | Disease Landscape and Forecast | G7 | 2018
The schizophrenia market is highly crowded given the presence of numerous antipsychotic therapies including the continued genericization of key oral therapies, the availability of newer oral atypical antipsychotics (e.g., Otsuka/Lundbeck’s Rexulti and Allergan/Gedeon Richter/Recordati’s Vraylar/Reagila), and the intensifying competition among long-acting injectables (LAIs). Indeed, to gain a foothold in the market, differentiation from already established therapies is a primary requirement for the late-phase and recently approved therapies—including new atypical antipsychotics (e.g., Alkermes’s ALKS-3831), new LAIs (e.g., Indivior’s Perseris, Janssen’s paliperidone six-month depot), and others (Intra-Cellular Therapies’ lumateperone, Minerva Neurosciences’ roluperidone, and Acadia Pharmaceuticals’ pimavanserin). Meanwhile, the potential of early- to mid-phase therapies for negative symptoms and cognitive impairment associated with schizophrenia, which are symptoms on which drug developers are increasingly focusing, remains to be seen.
Questions Answered
- What is the current size of the schizophrenia market in the G7 countries? What key events will influence the market over the next decade?
- What factors drive and constrain the use of LAIs of atypical antipsychotics? How is competition heating up in this segment?
- What are the biggest areas of unmet need? What is the line-up of emerging therapies, from early to late phase, with potential to fulfill these needs?
- What would key late-phase emerging therapies need to demonstrate to compete effectively in this crowded market?
Product Description: Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
Geographies: United States, EU5, Japan.
Primary research: 38 country-specific interviews with thought-leading psychiatrists, supported by survey data collected for this and other DRG research.
Epidemiology: Diagnosed prevalence of schizophrenia by country, segmented by positive symptoms and negative symptoms; drug-treated prevalence of schizophrenia by country.
Forecast: Ten-year, annualized, drug-level sales and patient share of key schizophrenia therapies through 2027, segmented by brands/generics.
Emerging therapies: Phase III/PR: 10 drugs. Phase II: 18 drugs. Coverage of select preclinical and Phase I products.
